ENSG00000065526 |
SPEN |
skin melanoma |
sequence_alteration |
6.627% (77/1162) |
2 entries |
ENSG00000065526 |
SPEN |
colorectal adenocarcinoma |
frameshift_variant |
7.192% (84/1168) |
3 entries |
ENSG00000065526 |
SPEN |
skin melanoma |
missense_variant |
6.627% (77/1162) |
7 entries |
ENSG00000065526 |
SPEN |
skin melanoma |
stop_gained |
6.627% (77/1162) |
2 entries |
ENSG00000065526 |
SPEN |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
6.462% (42/650) |
1 entry |
ENSG00000065526 |
SPEN |
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
6.462% (42/650) |
2 entries |
ENSG00000065526 |
SPEN |
breast ductal adenocarcinoma |
stop_gained |
5.254% (92/1751) |
4 entries |
ENSG00000065526 |
SPEN |
colorectal adenocarcinoma |
conservative_inframe_deletion |
7.192% (84/1168) |
1 entry |
ENSG00000065526 |
SPEN |
melanoma |
frameshift_variant |
16.55% (24/145) |
3 entries |
ENSG00000065526 |
SPEN |
breast ductal adenocarcinoma |
frameshift_variant |
5.254% (92/1751) |
7 entries |
ENSG00000065526 |
SPEN |
breast ductal adenocarcinoma |
sequence_alteration |
5.254% (92/1751) |
1 entry |
ENSG00000065526 |
SPEN |
breast ductal adenocarcinoma |
missense_variant |
5.254% (92/1751) |
5 entries |
ENSG00000065526 |
SPEN |
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
6.462% (42/650) |
1 entry |
ENSG00000065526 |
SPEN |
skin melanoma |
frameshift_variant |
6.627% (77/1162) |
2 entries |
ENSG00000065526 |
SPEN |
colorectal adenocarcinoma |
missense_variant |
7.192% (84/1168) |
4 entries |
ENSG00000065526 |
SPEN |
colorectal adenocarcinoma |
sequence_alteration |
7.192% (84/1168) |
2 entries |
ENSG00000065526 |
SPEN |
melanoma |
missense_variant |
16.55% (24/145) |
4 entries |
ENSG00000065526 |
SPEN |
breast carcinoma |
missense_variant |
3.145% (50/1590) |
3 entries |
ENSG00000065526 |
SPEN |
rectal adenocarcinoma |
frameshift_variant |
2.347% (13/554) |
1 entry |
ENSG00000065526 |
SPEN |
small cell lung carcinoma |
missense_variant |
2.709% (12/443) |
4 entries |
ENSG00000065526 |
SPEN |
lobular breast carcinoma |
missense_variant |
5.072% (14/276) |
1 entry |
ENSG00000065526 |
SPEN |
urothelial carcinoma |
missense_variant |
6.977% (6/86) |
1 entry |
ENSG00000065526 |
SPEN |
esophageal squamous cell carcinoma |
missense_variant |
3.039% (21/691) |
7 entries |
ENSG00000065526 |
SPEN |
hepatocellular carcinoma |
missense_variant |
2.134% (21/984) |
2 entries |
ENSG00000065526 |
SPEN |
melanoma |
conservative_inframe_deletion |
16.55% (24/145) |
1 entry |
ENSG00000065526 |
SPEN |
pharyngeal squamous cell carcinoma |
stop_gained |
3.497% (5/143) |
2 entries |
ENSG00000065526 |
SPEN |
marginal zone B-cell lymphoma |
stop_gained |
7.91% (14/177) |
2 entries |
ENSG00000065526 |
SPEN |
prostate carcinoma |
missense_variant |
3.097% (14/452) |
4 entries |
ENSG00000065526 |
SPEN |
pharyngeal squamous cell carcinoma |
missense_variant |
3.497% (5/143) |
2 entries |
ENSG00000065526 |
SPEN |
adenosquamous lung carcinoma |
missense_variant |
9.091% (2/22) |
1 entry |
ENSG00000065526 |
SPEN |
nasopharyngeal squamous cell carcinoma |
missense_variant |
3.247% (10/308) |
2 entries |
ENSG00000065526 |
SPEN |
squamous cell lung carcinoma |
missense_variant |
2.33% (24/1030) |
4 entries |
ENSG00000065526 |
SPEN |
colon adenocarcinoma |
sequence_alteration |
4.617% (59/1278) |
2 entries |
ENSG00000065526 |
SPEN |
rectal adenocarcinoma |
missense_variant |
2.347% (13/554) |
3 entries |
ENSG00000065526 |
SPEN |
colon adenocarcinoma |
conservative_inframe_deletion |
4.617% (59/1278) |
2 entries |
ENSG00000065526 |
SPEN |
female breast carcinoma |
stop_gained |
3.652% (13/356) |
1 entry |
ENSG00000065526 |
SPEN |
Sinonasal Undifferentiated Carcinoma |
frameshift_variant |
16.67% (2/12) |
1 entry |
ENSG00000065526 |
SPEN |
bile duct adenocarcinoma |
missense_variant |
0.7673% (3/391) |
2 entries |
ENSG00000065526 |
SPEN |
marginal zone B-cell lymphoma |
frameshift_variant |
7.91% (14/177) |
2 entries |
ENSG00000065526 |
SPEN |
gastric adenocarcinoma |
missense_variant |
4.306% (31/720) |
1 entry |
ENSG00000065526 |
SPEN |
prostate adenocarcinoma |
sequence_alteration |
3.628% (78/2150) |
1 entry |
ENSG00000065526 |
SPEN |
squamous cell lung carcinoma |
stop_gained |
2.33% (24/1030) |
1 entry |
ENSG00000065526 |
SPEN |
salivary gland adenoid cystic carcinoma |
frameshift_variant |
4.494% (4/89) |
1 entry |
ENSG00000065526 |
SPEN |
unspecified peripheral T-cell lymphoma |
missense_variant |
17.39% (4/23) |
1 entry |
ENSG00000065526 |
SPEN |
breast ductal adenocarcinoma |
conservative_inframe_deletion |
5.254% (92/1751) |
1 entry |
ENSG00000065526 |
SPEN |
cecum adenocarcinoma |
missense_variant |
7.17% (19/265) |
3 entries |
ENSG00000065526 |
SPEN |
clear cell renal carcinoma |
missense_variant |
1.375% (21/1527) |
1 entry |
ENSG00000065526 |
SPEN |
breast carcinoma |
stop_gained |
3.145% (50/1590) |
4 entries |
ENSG00000065526 |
SPEN |
lung adenocarcinoma |
missense_variant |
2.794% (71/2541) |
8 entries |
ENSG00000065526 |
SPEN |
gastric intestinal type adenocarcinoma |
missense_variant |
4.706% (4/85) |
1 entry |
ENSG00000065526 |
SPEN |
breast carcinoma |
frameshift_variant |
3.145% (50/1590) |
4 entries |
ENSG00000065526 |
SPEN |
T-cell acute lymphoblastic leukemia |
frameshift_variant |
0.7874% (3/381) |
2 entries |
ENSG00000065526 |
SPEN |
pancreatic neuroendocrine tumor |
missense_variant |
2.119% (5/236) |
1 entry |
ENSG00000065526 |
SPEN |
chronic lymphocytic leukemia |
stop_gained |
1.459% (13/891) |
1 entry |
ENSG00000065526 |
SPEN |
head and neck squamous cell carcinoma |
missense_variant |
0.7949% (5/629) |
1 entry |
ENSG00000065526 |
SPEN |
chronic lymphocytic leukemia |
missense_variant |
1.459% (13/891) |
1 entry |
ENSG00000065526 |
SPEN |
acute myeloid leukemia |
missense_variant |
1.322% (12/908) |
1 entry |
ENSG00000065526 |
SPEN |
female breast carcinoma |
frameshift_variant |
3.652% (13/356) |
3 entries |
ENSG00000065526 |
SPEN |
lung adenocarcinoma |
stop_gained |
2.794% (71/2541) |
2 entries |
ENSG00000065526 |
SPEN |
bronchoalveolar adenocarcinoma |
missense_variant |
9.091% (2/22) |
2 entries |
ENSG00000065526 |
SPEN |
Merkel cell skin cancer |
missense_variant |
9.474% (9/95) |
3 entries |
ENSG00000065526 |
SPEN |
HER2 Positive Breast Carcinoma |
missense_variant |
6.957% (8/115) |
3 entries |
ENSG00000065526 |
SPEN |
Parotid Gland Adenoid Cystic Carcinoma |
frameshift_variant |
11.11% (2/18) |
1 entry |
ENSG00000065526 |
SPEN |
prostate adenocarcinoma |
stop_gained |
3.628% (78/2150) |
2 entries |
ENSG00000065526 |
SPEN |
colon adenocarcinoma |
stop_gained |
4.617% (59/1278) |
2 entries |
ENSG00000065526 |
SPEN |
gastric intestinal type adenocarcinoma |
frameshift_variant |
4.706% (4/85) |
2 entries |
ENSG00000065526 |
SPEN |
pancreatic ductal adenocarcinoma |
frameshift_variant |
2.126% (36/1693) |
2 entries |
ENSG00000065526 |
SPEN |
anaplastic astrocytoma |
missense_variant |
2.19% (3/137) |
1 entry |
ENSG00000065526 |
SPEN |
nasopharyngeal squamous cell carcinoma |
stop_gained |
3.247% (10/308) |
2 entries |
ENSG00000065526 |
SPEN |
non-small cell lung carcinoma |
missense_variant |
3.81% (4/105) |
1 entry |
ENSG00000065526 |
SPEN |
Duodenal Adenocarcinoma |
missense_variant |
11.76% (2/17) |
1 entry |
ENSG00000065526 |
SPEN |
follicular thyroid carcinoma |
stop_gained |
2.857% (2/70) |
1 entry |
ENSG00000065526 |
SPEN |
gastric adenocarcinoma |
stop_gained |
4.306% (31/720) |
2 entries |
ENSG00000065526 |
SPEN |
Invasive Breast Carcinoma |
stop_gained |
6.383% (3/47) |
1 entry |
ENSG00000065526 |
SPEN |
diffuse gastric adenocarcinoma |
sequence_alteration |
4.878% (4/82) |
1 entry |
ENSG00000065526 |
SPEN |
clear cell renal carcinoma |
sequence_alteration |
1.375% (21/1527) |
1 entry |
ENSG00000065526 |
SPEN |
brain glioblastoma |
missense_variant |
1.144% (14/1224) |
3 entries |
ENSG00000065526 |
SPEN |
marginal zone B-cell lymphoma |
missense_variant |
7.91% (14/177) |
2 entries |
ENSG00000065526 |
SPEN |
lung adenocarcinoma |
conservative_inframe_deletion |
2.794% (71/2541) |
1 entry |
ENSG00000065526 |
SPEN |
Prostate Small Cell Carcinoma |
conservative_inframe_deletion |
10.53% (2/19) |
1 entry |
ENSG00000065526 |
SPEN |
ovarian serous adenocarcinoma |
sequence_alteration |
1.671% (14/838) |
2 entries |
ENSG00000065526 |
SPEN |
salivary gland adenoid cystic carcinoma |
stop_gained |
4.494% (4/89) |
1 entry |
ENSG00000065526 |
SPEN |
glioma |
missense_variant |
0.3268% (2/612) |
1 entry |
ENSG00000065526 |
SPEN |
anaplastic astrocytoma |
stop_gained |
2.19% (3/137) |
2 entries |
ENSG00000065526 |
SPEN |
diffuse large B-cell lymphoma |
missense_variant |
2.075% (10/482) |
3 entries |
ENSG00000065526 |
SPEN |
ovarian serous adenocarcinoma |
missense_variant |
1.671% (14/838) |
2 entries |
ENSG00000065526 |
SPEN |
esophageal adenocarcinoma |
missense_variant |
4.015% (22/548) |
2 entries |
ENSG00000065526 |
SPEN |
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
3.247% (10/308) |
2 entries |
ENSG00000065526 |
SPEN |
lobular breast carcinoma |
stop_gained |
5.072% (14/276) |
1 entry |
ENSG00000065526 |
SPEN |
papillary renal cell carcinoma |
missense_variant |
2.062% (8/388) |
1 entry |
ENSG00000065526 |
SPEN |
diffuse large B-cell lymphoma |
stop_gained |
2.075% (10/482) |
4 entries |
ENSG00000065526 |
SPEN |
bladder carcinoma |
missense_variant |
4.991% (28/561) |
1 entry |
ENSG00000065526 |
SPEN |
prostate adenocarcinoma |
missense_variant |
3.628% (78/2150) |
4 entries |
ENSG00000065526 |
SPEN |
hairy cell leukemia |
missense_variant |
9.524% (2/21) |
1 entry |
ENSG00000065526 |
SPEN |
bladder transitional cell carcinoma |
frameshift_variant |
6.144% (29/472) |
1 entry |
ENSG00000065526 |
SPEN |
Breast Carcinoma by Gene Expression Profile |
stop_gained |
10.0% (4/40) |
1 entry |
ENSG00000065526 |
SPEN |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
1.894% (5/264) |
2 entries |
ENSG00000065526 |
SPEN |
Gallbladder Adenocarcinoma |
sequence_alteration |
2.143% (3/140) |
1 entry |
ENSG00000065526 |
SPEN |
colon adenocarcinoma |
frameshift_variant |
4.617% (59/1278) |
4 entries |
ENSG00000065526 |
SPEN |
pancreatic ductal adenocarcinoma |
missense_variant |
2.126% (36/1693) |
2 entries |
ENSG00000065526 |
SPEN |
colon adenocarcinoma |
missense_variant |
4.617% (59/1278) |
10 entries |
ENSG00000065526 |
SPEN |
prostate carcinoma |
sequence_alteration |
3.097% (14/452) |
1 entry |
ENSG00000065526 |
SPEN |
anaplastic oligodendroglioma |
missense_variant |
5.747% (5/87) |
2 entries |
ENSG00000065526 |
SPEN |
bladder transitional cell carcinoma |
missense_variant |
6.144% (29/472) |
5 entries |
ENSG00000065526 |
SPEN |
breast ductal adenocarcinoma |
amino_acid_insertion |
5.254% (92/1751) |
1 entry |
ENSG00000065526 |
SPEN |
lobular breast carcinoma |
frameshift_variant |
5.072% (14/276) |
2 entries |
ENSG00000065526 |
SPEN |
Cervical Small Cell Carcinoma |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000065526 |
SPEN |
female breast carcinoma |
missense_variant |
3.652% (13/356) |
2 entries |
ENSG00000065526 |
SPEN |
oral squamous cell carcinoma |
missense_variant |
3.371% (9/267) |
5 entries |
ENSG00000065526 |
SPEN |
cecum adenocarcinoma |
frameshift_variant |
7.17% (19/265) |
1 entry |
ENSG00000065526 |
SPEN |
prostate adenocarcinoma |
frameshift_variant |
3.628% (78/2150) |
2 entries |
ENSG00000065526 |
SPEN |
laryngeal squamous cell carcinoma |
sequence_alteration |
7.317% (3/41) |
1 entry |
ENSG00000065526 |
SPEN |
neuroendocrine carcinoma |
missense_variant |
28.57% (2/7) |
1 entry |
ENSG00000065526 |
SPEN |
Gastrointestinal stromal tumor |
missense_variant |
1.316% (2/152) |
1 entry |
ENSG00000065526 |
SPEN |
basal cell carcinoma |
missense_variant |
11.76% (8/68) |
2 entries |
ENSG00000065526 |
SPEN |
esophageal adenocarcinoma |
sequence_alteration |
4.015% (22/548) |
1 entry |
ENSG00000065526 |
SPEN |
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
10.0% (4/40) |
1 entry |
ENSG00000065526 |
SPEN |
atypical teratoid rhabdoid tumor |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000065526 |
SPEN |
multiple myeloma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000065526 |
SPEN |
cecum adenocarcinoma |
stop_gained |
7.17% (19/265) |
1 entry |
ENSG00000065526 |
SPEN |
mucosal melanoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000065526 |
SPEN |
nasal cavity and paranasal sinus carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000065526 |
SPEN |
Invasive Breast Carcinoma |
missense_variant |
6.383% (3/47) |
1 entry |
ENSG00000065526 |
SPEN |
adrenal cortex carcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000065526 |
SPEN |
Ovarian Choriocarcinoma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000065526 |
SPEN |
T-cell acute lymphoblastic leukemia |
missense_variant |
0.7874% (3/381) |
1 entry |
ENSG00000065526 |
SPEN |
diffuse large B-cell lymphoma |
sequence_alteration |
2.075% (10/482) |
1 entry |
ENSG00000065526 |
SPEN |
extragonadal nonseminomatous germ cell tumor |
missense_variant |
6.667% (1/15) |
1 entry |
ENSG00000065526 |
SPEN |
non-small cell lung carcinoma |
frameshift_variant |
3.81% (4/105) |
1 entry |
ENSG00000065526 |
SPEN |
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
0.8929% (4/448) |
1 entry |
ENSG00000065526 |
SPEN |
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000065526 |
SPEN |
lung carcinoid tumor |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000065526 |
SPEN |
Borderline Ovarian Mucinous Tumor |
frameshift_variant |
12.5% (1/8) |
1 entry |
ENSG00000065526 |
SPEN |
papillary thyroid carcinoma |
stop_gained |
0.4073% (2/491) |
1 entry |
ENSG00000065526 |
SPEN |
Ovarian Sertoli-Leydig Cell Tumor |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000065526 |
SPEN |
Testicular Yolk Sac Tumor |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000065526 |
SPEN |
papillary thyroid carcinoma |
missense_variant |
0.4073% (2/491) |
1 entry |
ENSG00000065526 |
SPEN |
head and neck squamous cell carcinoma |
conservative_inframe_deletion |
0.7949% (5/629) |
1 entry |
ENSG00000065526 |
SPEN |
soft tissue sarcoma |
missense_variant |
0.6803% (2/294) |
1 entry |
ENSG00000065526 |
SPEN |
small intestinal adenocarcinoma |
frameshift_variant |
4.762% (1/21) |
1 entry |
ENSG00000065526 |
SPEN |
ovarian sarcoma |
stop_gained |
100.0% (1/1) |
1 entry |
ENSG00000065526 |
SPEN |
laryngeal squamous cell carcinoma |
missense_variant |
7.317% (3/41) |
1 entry |
ENSG00000065526 |
SPEN |
small cell carcinoma |
frameshift_variant |
33.33% (1/3) |
1 entry |
ENSG00000065526 |
SPEN |
Uterine Carcinosarcoma |
stop_gained |
2.027% (3/148) |
1 entry |
ENSG00000065526 |
SPEN |
pseudomyxoma peritonei |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000065526 |
SPEN |
diffuse gastric adenocarcinoma |
frameshift_variant |
4.878% (4/82) |
1 entry |
ENSG00000065526 |
SPEN |
prostate carcinoma |
frameshift_variant |
3.097% (14/452) |
1 entry |
ENSG00000065526 |
SPEN |
Kidney Medullary Carcinoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000065526 |
SPEN |
diffuse large B-cell lymphoma |
frameshift_variant |
2.075% (10/482) |
1 entry |
ENSG00000065526 |
SPEN |
soft tissue sarcoma |
frameshift_variant |
0.6803% (2/294) |
1 entry |
ENSG00000065526 |
SPEN |
unspecified peripheral T-cell lymphoma |
conservative_inframe_deletion |
17.39% (4/23) |
1 entry |
ENSG00000065526 |
SPEN |
osteosarcoma |
missense_variant |
0.6579% (1/152) |
1 entry |
ENSG00000065526 |
SPEN |
Salivary Gland Carcinoma ex Pleomorphic Adenoma |
stop_gained |
4.167% (1/24) |
1 entry |
ENSG00000065526 |
SPEN |
salivary gland carcinoma |
stop_gained |
6.061% (2/33) |
1 entry |
ENSG00000065526 |
SPEN |
Breast Carcinoma by Gene Expression Profile |
missense_variant |
10.0% (4/40) |
1 entry |
ENSG00000065526 |
SPEN |
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000065526 |
SPEN |
salivary gland carcinoma |
sequence_alteration |
6.061% (2/33) |
1 entry |
ENSG00000065526 |
SPEN |
Pancreatic Acinar Cell Carcinoma |
stop_gained |
2.941% (1/34) |
1 entry |
ENSG00000065526 |
SPEN |
Gallbladder Adenocarcinoma |
missense_variant |
2.143% (3/140) |
1 entry |
ENSG00000065526 |
SPEN |
metaplastic breast carcinoma |
missense_variant |
3.226% (2/62) |
1 entry |
ENSG00000065526 |
SPEN |
colon carcinoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000065526 |
SPEN |
Signet Ring Cell Gastric Adenocarcinoma |
amino_acid_insertion |
33.33% (1/3) |
1 entry |
ENSG00000065526 |
SPEN |
Gastric Neuroendocrine Tumor G1 |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000065526 |
SPEN |
angioimmunoblastic T-cell lymphoma |
stop_gained |
4.545% (1/22) |
1 entry |
ENSG00000065526 |
SPEN |
diffuse gastric adenocarcinoma |
missense_variant |
4.878% (4/82) |
1 entry |
ENSG00000065526 |
SPEN |
chromophobe renal cell carcinoma |
missense_variant |
0.6757% (1/148) |
1 entry |
ENSG00000065526 |
SPEN |
anaplastic large cell lymphoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000065526 |
SPEN |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
1.894% (5/264) |
1 entry |
ENSG00000065526 |
SPEN |
Ampulla of Vater Carcinoma |
stop_gained |
2.353% (2/85) |
1 entry |
ENSG00000065526 |
SPEN |
Malignant Germ Cell Tumor |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000065526 |
SPEN |
Placental Choriocarcinoma |
missense_variant |
20.0% (1/5) |
1 entry |
ENSG00000065526 |
SPEN |
Pleural Mesothelioma |
missense_variant |
1.471% (2/136) |
1 entry |
ENSG00000065526 |
SPEN |
Parathyroid Gland Carcinoma |
frameshift_variant |
5.263% (1/19) |
1 entry |
ENSG00000065526 |
SPEN |
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
1.316% (1/76) |
1 entry |
ENSG00000065526 |
SPEN |
bladder transitional cell carcinoma |
stop_gained |
6.144% (29/472) |
1 entry |
ENSG00000065526 |
SPEN |
pharyngeal squamous cell carcinoma |
conservative_inframe_deletion |
3.497% (5/143) |
1 entry |
ENSG00000065526 |
SPEN |
Appendix Goblet Cell Carcinoid |
missense_variant |
4.762% (1/21) |
1 entry |
ENSG00000065526 |
SPEN |
ovarian serous adenocarcinoma |
stop_gained |
1.671% (14/838) |
1 entry |
ENSG00000065526 |
SPEN |
Ampulla of Vater Carcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000065526 |
SPEN |
Thymic Carcinoma |
stop_gained |
10.0% (1/10) |
1 entry |
ENSG00000065526 |
SPEN |
brain glioblastoma |
sequence_alteration |
1.144% (14/1224) |
1 entry |
ENSG00000065526 |
SPEN |
Mantle cell lymphoma |
frameshift_variant |
1.887% (1/53) |
1 entry |
ENSG00000065526 |
SPEN |
Merkel cell skin cancer |
sequence_alteration |
9.474% (9/95) |
1 entry |
ENSG00000065526 |
SPEN |
metaplastic breast carcinoma |
frameshift_variant |
3.226% (2/62) |
1 entry |
ENSG00000065526 |
SPEN |
squamous cell lung carcinoma |
frameshift_variant |
2.33% (24/1030) |
1 entry |
ENSG00000065526 |
SPEN |
Uterine Carcinosarcoma |
missense_variant |
2.027% (3/148) |
1 entry |
ENSG00000065526 |
SPEN |
papillary renal cell carcinoma |
frameshift_variant |
2.062% (8/388) |
1 entry |
ENSG00000065526 |
SPEN |
large cell lung carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000065526 |
SPEN |
anaplastic oligodendroglioma |
sequence_alteration |
5.747% (5/87) |
1 entry |
ENSG00000065526 |
SPEN |
neoplasm of mature B-cells |
frameshift_variant |
1.639% (1/61) |
1 entry |
ENSG00000065526 |
SPEN |
astrocytoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000065526 |
SPEN |
small cell carcinoma |
stop_gained |
33.33% (1/3) |
1 entry |
ENSG00000065526 |
SPEN |
Anal Squamous Cell Carcinoma |
missense_variant |
1.205% (1/83) |
1 entry |
ENSG00000065526 |
SPEN |
Brain Stem Glioblastoma |
missense_variant |
1.786% (1/56) |
1 entry |
ENSG00000065526 |
SPEN |
basal cell carcinoma |
stop_gained |
11.76% (8/68) |
1 entry |
ENSG00000065526 |
SPEN |
kidney Wilms tumor |
stop_gained |
0.3115% (1/321) |
1 entry |
ENSG00000065526 |
SPEN |
acute lymphoblastic leukemia |
missense_variant |
0.3115% (1/321) |
1 entry |
ENSG00000065526 |
SPEN |
solitary fibrous tumor |
missense_variant |
3.448% (1/29) |
1 entry |
ENSG00000065526 |
SPEN |
Pleural Mesothelioma |
frameshift_variant |
1.471% (2/136) |
1 entry |